DoseSpot
DoseSpot, a rapidly growing healthcare SaaS company, is seeking a Level 2 Technical Support Specialist to provide advanced troubleshooting and support for internet-based applications and systems. The role involves collaborating with various teams to resolve complex technical issues, improve support processes, and enhance customer satisfaction. It offers the opportunity to work remotely in a fast-paced, innovative environment at the intersection of healthcare and technology.
Headquarters
Boston, Massachusetts, United States
Company Size
51-200 employees
Founded
2009
DoseSpot is a leading certified ePrescribing platform designed for healthcare providers, enabling them to send prescriptions electronically with improved safety and efficiency. The platform integrates seamlessly with various healthcare solutions, offering features such as real-time medication pricing, electronic prior authorization, and patient engagement tools. Founded in 2009, DoseSpot aims to streamline patient care and foster better health outcomes through innovative technology tailored for diverse healthcare industries. With a strong focus on compliance and user-friendly interfaces, it supports a wide range of medical practices and enhances the prescribing process across the healthcare spectrum.
DoseSpot, Arrive Health merge to combine prescribing tools with pharmacy, medical benefit data
2 weeks ago
Interra Health, created through the merger of DoseSpot and
2 weeks ago
M&A: DoseSpot and Arrive Health Merge to Form Interra Health, Advancing ePrescribing Price Transparency
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for DoseSpot.
DoseSpot study: Many patients are overpaying for GLP-1s
Jun 23, 2025